The Institute of Pharmaceutical Innovation

Monday 21st August, 2006 Prosthetic Solutions gain MHRA approval

The Medicines and Healthcare Regulatory Agency has given approval to Proshetic Solutions application to market Zeflosil, a revolutionary new adhesive for the attachment of prostheses to skin.

PRESS RELEASE
Date: 17th August 2006

Revolutionary Adhesive for Prostheses Saves the NHS Money!

Professor Alan Roberts OBE, has made a major break through for the plastic and reconstructive surgery field by masterminding and developing – Zeflosil, a prosthetic adhesive, which is used to attach devices to the skin.

‘Zeflosil is the first product of its kind to be produced in the UK’, said Professor Roberts’, ‘it can be used on patients who have had any cancer reconstructive surgery or on patients undertaking colostomy treatments, and also on the attachment of diagnostic devices’, he added.
Zeflosil will be marketed through Prosthetic Solutions Ltd, a company recently established by Professor Roberts. Prosthetic Solutions is based in the Bioscience Business Incubator at the University of Bradford’s Institute of Pharmaceutical Innovation (IPI)
‘It was an excellent choice to be based at the IPI as I have access to pharmaceutical analysis, expertise and equipment, and a wide network of business services and support’, said Professor Roberts.
The IPI incubator provides new companies a prestigious address, laboratory and office space and a support system during their early development’, said Dr Kevin Adams, Bioscience Business Incubator Manager, ‘It is really exciting to see Prosthetic Solutions get their first product to market. It’s even better when you know that there are more significant developments in the pipeline.’ he added.
During clinical trials Zeflosil exceeded all expectations and has recently achieved quality standards such as CE marking (EU approval), and approval by MHRA (Medicines and Healthcare Products Regulatory Agency)
‘Using Zeflosil gives the patient ease of application, other benefits include durability and cost effectiveness compared with other products available in the market place’, said Professor Roberts. ‘In fact, I am currently in discussion with senior management from NHS Trusts following the results of Zeflosil’’, he added.
Professor Roberts specialises as a Consultant Clinical Scientist, he is a former Director of the Centre for Clinical Prosthetics, Department of Plastic and Maxillo-Facial Surgery; and former Director for Research and Development for Bradford Teaching Hospitals NHS Trust.
He is currently Chairman of the Bradford Research Ethics Committee and Professor of Biomaterials in Surgery at the Academic Surgical Unit, Schools of Medicine, University of Hull and Honorary Professor of Biomaterials, University of Bradford. Professor Roberts has received many National Honours and Awards and has an International standing in the field of Material Science in medicine.